[Studies on actoprotective and antihypoxic properties of new succinate-containing benzothiazole derivatives].
Experiments with mice demonstrated that in contrast to the preparations for comparison (mexidol and reference antihypoxant succinate amtisol at a dose of 1-100 mg/kg) new succinate-containing derivatives of benzothiazole BTI-2 (0.5-5 mg/kg), BTI-3 (0.1, 0.5 and 10 mg/kg), 877-4 (0.5 mg/kg) and BTI-5 (0.5 and 1 mg/kg) improved physical performance of animals by 18-56 and 21-39% in the treadmill test and swimming test (positive effect of BTI-4 and -5 only), respectively. In all three models of acute hypoxia (normobaric hypoxic hypoxia with hyperkapnia, histotoxic and hemic) an obvious antihypoxic activity was displayed by BTI-1 and -2 only. In comparison with mexidol and succinate amtizol, positive and stronger effect of these compounds was achieved at significantly lower doses. Therefore, the succinate-containing benzothiazole derivatives have considerable promise as ingredients of performance enhancing antihypoxic and therapeutic compositions.